June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Intraocular pharmacokinetics of bevacizumab and ranibizumab in vitrectomized versus non-vitrectomized rabbit eyes
Author Affiliations & Notes
  • Jeeyun Ahn
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
  • Sunyoung Park
    Department of Chemical & Biomolecular Engineering, Sogang University, Seoul, Republic of Korea
  • Hyuncheol Kim
    Department of Chemical & Biomolecular Engineering, Sogang University, Seoul, Republic of Korea
    Interdisciplinary Program of integrated Biotechnology, Sogang University, Seoul, Republic of Korea
  • Ji Hyun Park
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Ji Yeon Park
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Duck Jin Hwang
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Seong Joon Ahn
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Yong-Kyu Kim
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Kyu Hyung Park
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Se Joon Woo
    Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Republic of Korea
    Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
  • Footnotes
    Commercial Relationships Jeeyun Ahn, None; Sunyoung Park, None; Hyuncheol Kim, None; Ji Hyun Park, None; Ji Yeon Park, None; Duck Jin Hwang, None; Seong Joon Ahn, None; Yong-Kyu Kim, None; Kyu Hyung Park, None; Se Joon Woo, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1080. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jeeyun Ahn, Sunyoung Park, Hyuncheol Kim, Ji Hyun Park, Ji Yeon Park, Duck Jin Hwang, Seong Joon Ahn, Yong-Kyu Kim, Kyu Hyung Park, Se Joon Woo; Intraocular pharmacokinetics of bevacizumab and ranibizumab in vitrectomized versus non-vitrectomized rabbit eyes. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1080.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To analyze intraocular pharmacokinetic properties of bevacizumab and ranibizumab in vitrectomized and non-vitrectomized rabbit eyes.

Methods: Twenty-five-gauge pars plana vitrectomy without lensectomy was performed in 35 rabbit eyes and 36 non-vitrectomized rabbit eyes served as control. Intravitreal injection of 1.25mg/0.05mL bevacizumab was performed in 17 vitrectomized (group 1-1) and 18 non-vitrectomized (group 1-2) eyes, respectively. Intravitreal injection of 0.25mg/0.025mL ranibizumab was performed in 18 vitrectomized (group 2-1) and 18 non-vitrectomized (group 2-2) eyes, respectively. Eyes were enucleated at 1 hour, 1, 2, 5, 14 and 30 days after the intravitreal injections and frozen at -80°C. Bevacizumab and ranibizumab concentrations in the vitreous and aqueous humor, as well as the retina/choroid, were determined using direct enzyme-linked immunosorbent assay.

Results: Vitreous clearance of bevacizumab and ranibizumab showed distinct patterns, consisting of 2 phases and 1 phase, respectively. The vitreous half-life of bevacizumab and ranibizumab were 6.99, 7.06, 2.51 and 2.75 days in vitrectomized and non-vitrectomized eyes, respectively.

Conclusions: Vitrectomy did not substantially affect pharmacokinetic properties or chorioretinal concentrations of intravitreally injected bevacizumab or ranibizumab in rabbit eyes.

Keywords: 763 vitreous • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×